Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, ...

(REGN) on Friday reported second-quarter earnings of $1.39 billion. The Tarrytown, New York-based company said it ...

See the latest Regeneron Pharmaceuticals Inc stock price (REGN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project.

Review the current Regeneron Pharmaceuticals Inc (REGN:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if REGN is the best investment for you.

Regeneron has moved closer to a regulatory filing for its BCMAxCD3 bispecific antibody linvoseltamab, the first of a series of bispecifics that is spearheading its oncology pipeline.

The biopharmaceutical industry is growing rapidly as a result of significant advancements in biotechnology and drug ...

Check out the latest Regeneron Pharmaceuticals Inc. (REGN) stock quote and chart. View real-time stock prices & the company’s financial overview to help with your trading & investment.